TB Online is no longer maintained. This is an archive of the site. For news on TB please go to:
https://globaltbcab.org/Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant
Valneva SE
Dec. 11, 2014, 10:44 p.m.
Clinical trial in HIV-infected adults showed good safety and immunogenicity
To download the press release, click here.
Source: Valneva SE